Published in

American Diabetes Association, Diabetes, Supplement_1(68), 2019

DOI: 10.2337/db19-446-p

Links

Tools

Export citation

Search in Google Scholar

446-P: Associations of Blood Pressure (BP) with Incidence of Coronary Artery Disease (CAD)/Cerebrovascular Disease (CVD) According to Glucose Tolerance Status (GTS)

Journal article published in 2019 by Mayuko Harada, Kazuya Fujihara, Masahiko Yamamoto, Masanori Kaneko, Masaru Kitazawa, Hiroshi Suzuki, Yasuhiro Matsubayashi, Takaho Yamada, Nauta Yamanaka, Hiroyasu Seida, Wataru Ogawa, Hirohito Sone
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Although the 2017 ACC/AHA guidelines indicated a generalized BP goal of less than 130/80 mm Hg, the impact of BP separately on CAD or CVD in people with different GTSs has yet to be clarified. To clarify this, data from a nationwide claims database involving 293,396 participants without prior CAD or CVD during 2008-16 were analyzed. Multivariate Cox regression model was used to identify risks of a CAD and/or CVD event. Hazard ratios (HRs) were compared among 4 groups of participants divided according to stratified levels of BP [i.e., <130/90 mmHg, systolic BP (SBP) =130-139 and/or diastolic BP (DBP) =80-89 mmHg, SBP≥140 or DBP>90 mmHg, ≥140/90 mmHg] according to GTS [i.e., normal glucose tolerance (NGT), prediabetes (pre-DM), diabetes mellitus (DM)]. During the study period, 1099 CAD and 1990 CVD events occurred. Despite that a significant trend between BP and incident CAD was observed regardless of GTS, risk for CVD was dependent on BP only in the NGT and pre-DM groups. Moreover, there were no significant differences in CVD risks between categories of BP<130/90 mmHg and SBP=130-139 and/or DBP=80-89 mmHg among patients with DM. These results implied the necessity of setting specific BP goals according to GTS for prevention of CAD/CVD. Disclosure M. Harada: None. K. Fujihara: None. M. Yamamoto: None. M. Kaneko: None. M. Kitazawa: None. H. Suzuki: None. Y. Matsubayashi: None. T. Yamada: None. N. Yamanaka: None. H. Seida: None. W. Ogawa: Consultant; Self; Abbott. Research Support; Self; Astellas Pharma Inc., AstraZeneca, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited. Speaker's Bureau; Self; Lilly Diabetes, Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Sanofi, Sumitomo Dainippon Pharma Co., Ltd. H. Sone: Research Support; Self; Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Kowa Pharmaceutical Europe Co. Ltd., Kyowa Hakko Kirin Co., Ltd., Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited.